New potent bisubstrate inhibitors of histone acetyltransferase p300: design, synthesis and biological evaluation

Chem Biol Drug Des. 2011 Jan;77(1):86-92. doi: 10.1111/j.1747-0285.2010.01056.x. Epub 2010 Nov 30.

Abstract

Bisubstrate-type compound Lys-CoA has been shown to inhibit the p300 histone acetyl transferase activity efficiently and may constitute a lead compound for a novel class of anticancer therapeutics. Based on this strategy, we synthesized a series of CoA derivatives and evaluated these molecules for their activity as p300 histone acetyltransferases inhibitor. The best activity was obtained with compound 3 bearing a C-5 spacing linker that connects the CoA moiety to a tert-butyloxycarbonyl (Boc) group. Based on docking simulations, this inhibitor exhibits favorable interactions with two binding areas, namely pockets P1 and P2, within the active site.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / chemical synthesis*
  • Amides / pharmacology*
  • Coenzyme A / chemical synthesis*
  • Coenzyme A / pharmacology*
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / pharmacology*
  • Histone Acetyltransferases* / antagonists & inhibitors
  • Histone Acetyltransferases* / metabolism
  • Models, Molecular
  • Molecular Dynamics Simulation
  • Protein Binding
  • Reproducibility of Results
  • Research Design

Substances

  • Amides
  • Enzyme Inhibitors
  • Histone Acetyltransferases
  • Coenzyme A